Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-04-04

FDA Approved: AMBRISENTAN — Supplemental Application (Mylan Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for a generic version of ambrisentan, used to treat pulmonary arterial hypertension. Mylan Pharmaceuticals Inc. is the a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)